Predictors of the use of analgesic drugs 1 year after joint replacement: a single-center analysis of 13,000 hip and knee replacements

CURRENT STATUS: ACCEPTED

Arthritis Research & Therapy  ● BMC

Tuomas Rajamäki
Tampereen Yliopisto

✉ tuomas.rajamaki@outlook.com Corresponding Author
ORCiD: https://orcid.org/0000-0002-7089-6987

Pia A. Puolakka
Tampereen yliopistollinen sairaala

Aki Hietaharju
Tampereen yliopistollinen sairaala

Teemu Moilanen
Tekonivelsairaala Coxa Oy

Esa Jämsen
Tampereen Yliopisto

DOI:
10.21203/rs.2.22146/v1

SUBJECT AREAS
Anesthesiology & Pain Medicine

KEYWORDS
knee replacement, hip replacement, analgesic drug, opioid, NSAID, acetaminophen, risk factors
Abstract

**Background:** Pain persists in a moderate number of patients following hip or knee replacement surgery. Persistent pain may subsequently lead to the prolonged consumption of analgesics after surgery and expose patients to the adverse drug events of opioids and NSAIDs, especially in older patients and patients with comorbidities. This study aimed to identify risk factors for the increased use of opioids and other analgesics one year after surgery and focused on comorbidities and surgery-related factors.

**Methods:** All patients who underwent a primary hip or knee replacement for osteoarthritis from 2002 to 2013 were identified. Redeemed prescriptions for acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids (mild and strong) were collected from a nationwide Drug Prescription Register. The user rates of analgesics and the adjusted odds ratios for analgesic use one year after joint replacement were calculated.

**Results:** Of the 6,238 hip replacement and 7,501 knee replacement recipients, 3,591 (26.1%) were still using analgesics one year after surgery. Significant predictors of overall analgesic use (acetaminophen, NSAID, or opioid) were (odds ratio (95% CI)) age 65-74.9 years (reference <65), 1.2 (1.04-1.3), age > 75 years, 1.3 (1.2-1.5), female gender, 1.3 (1.2-1.4), BMI 30-34.9 kg/m2 (reference <25kg/m2), 1.2 (1.03-1.5), BMI >35 kg/m2, 1.7 (1.4-2.2), a higher number of comorbidities (according to modified Charlson Comorbidity Index score), 1.4 (1.2-1.6), and hypertension, 1.1 [1.00–1.2]. Diabetes and other comorbidities were not significant independent predictors. Of the other clinical factors, the preoperative use of analgesics, 4.0 (3.6-4.3) and knee surgery, 1.3 (1.2-1.4), predicted the use of analgesics, whereas simultaneous bilateral knee replacement (compared to unilateral procedure) was a protective factor, 0.80 (0.70-0.92). Opioid use was associated with obesity, higher CCI score, epilepsy, knee vs hip surgery, unilateral vs bilateral knee operation, total vs unicompartamental knee replacement, and the preoperative use of analgesics/opioids.

**Conclusions:** Obesity (especially BMI >35 kg/m2) and the preoperative use of analgesics were the strongest predictors of an increased postoperative use of analgesics. It is remarkable that also older age and higher number of comorbidities predicted analgesic use despite these patients being the
most vulnerable to adverse drug events.

Introduction

Although hip and knee replacement are performed to reduce pain and regain function in patients with late-stage arthritis (1,2), 10-20% of patients continue to suffer from persistent pain after surgery (3,4). The latest studies focusing on persistent pain indicate that its major risk factors include pain catastrophizing, intensity of preoperative pain, mental health problems, knee surgery, and certain comorbidities, such as diabetes (4–7).

Persistent pain may also lead to the increased consumption of analgesics (8). To date, however, only a limited number of large-scale studies have been conducted on the trajectories of analgesic consumption and the risk factors associated with increased analgesic consumption after surgery (9–21), even though the risks for adverse events of opioids and non-steroidal anti-inflammatory drugs increase in long-term use (22–24), especially in elderly patients with comorbidities. Motivated by the ongoing opioid prescription crisis (25), most recent studies have focused on opioid use after joint replacement and reported higher odds for prolonged postoperative opioid use in association with psychiatric disorders, preoperative opioid use, worse preoperative pain, younger age, cardiac disease, and undergoing knee (compared to hip) surgery (9,10,14–20,26).

The analysis of persistent pain should also include non-opioid analgesics, which at present only applies to a few studies (9,11,12,21). Indeed, high levels of preoperative pain, knee surgery (compared to hip surgery), and younger age have all been associated with an increased overall consumption of analgesic drugs (9). Furthermore, obesity, female gender, younger age, and depression are associated with an increased consumption of NSAIDs (11,12,21). However, general comorbidities, such as diabetes, a risk factor for persistent pain, have only been analyzed in one previous study (9), in which no differences in overall analgesic consumption after knee replacement were reported. To the best of our knowledge, those factors related to the consumption of acetaminophen have not previously been analyzed in the literature.

In our study, we studied the use of opioids, NSAIDs, and acetaminophen in a large sample of patients undergoing primary hip or knee replacement for osteoarthritis. Our primary aim was to find out
whether postoperative analgesic use is associated with patient characteristics, such as obesity or other comorbidities, or other clinical factors such as preoperative pain, function, and analgesic use. Our secondary aim was to find out whether these factors differ depending on the type of analgesic used.

Patients And Methods
The study population
A total of 13,261 hip replacements and 13,205 knee replacements were performed between September 2, 2002 and December 31, 2013 in a single, publicly-funded orthopaedic hospital in Finland, as reported in a previous study (27). A prospective database of the hospital includes preoperative and postoperative clinical information on these patients. All patients who had undergone a primary operation and had primary osteoarthritis as the indication for surgery were included in this study. Patients with revisions or other joint replacements during the study period (operation date +/- two years) were excluded. Finally, 13,739 joint replacements (6,238 hip replacements performed on 5,657 patients and 7,501 knee replacements performed on 6,791 patients) were included (Figure 1).

Special Reimbursement Register
Finland has a health insurance system that covers all residents. A share of the costs of prescribed medications are reimbursed by the Social Insurance Institution (SII). Patients with certain severe and chronic diseases are entitled to special refunds. To be eligible for special reimbursement, a written certificate that verifies the patient’s condition meets the predefined criteria is required from the treating physician. The SII maintains a Special Reimbursement Register that was used to extract information on chronic diseases for this study. The chronic diseases include Alzheimer’s disease, cardiac disease (coronary heart disease, heart failure, and chronic arrhythmias), hypertension, diabetes, epilepsy, malignancies, asthma or other severe obstructive pulmonary disease, severe kidney disease, Parkinson’s disease, psychoses, and rheumatic diseases.

Medication data
In addition to the Special Reimbursement Register, the SII also maintains a nationwide Drug Prescription Register that contains information on all prescribed medications that have been dispensed from pharmacies in Finland. In this study, information on the Anatomical Therapeutic
Chemical (ATC) code of the dispensed drugs, the number of units dispensed (tablets or patches), and the date of purchase was collected from the Drug Prescription Register two years prior to and after surgery. The analyzed analgesics were acetaminophen (N02BE01), NSAIDs (including coxibs; M01A), and opioids (N02A). Depression is a significant risk factor for persistent pain and analgesic use (4,5,9,11,21,26), and therefore information on antidepressant (N06A) purchases within a period of 1 year prior to surgery was registered to act as an indicator of depression because only psychotic depression is recorded in the Special Reimbursement Register. Over-the-counter (OTC) drugs, which in Finland include small packs of acetaminophen, ibuprofen, and ketoprofen, were not recorded in this study. However, patients with chronic painful conditions, such as osteoarthritis, often redeem analgesics with a prescription because they are significantly less expensive. In Finland, all medications (including OTC-drugs) are sold from pharmacies.

Statistics
The proportions of patients who redeemed at least one prescription of the studied medication were calculated in time-periods of three months (90 days), two years preoperatively, and two years postoperatively. The analgesic groups included opioids, NSAIDs, acetaminophen, and any analgesics (previous groups combined).

In this study, the focus was on those factors associated with the use of analgesics preoperatively (0-3 months before surgery) and 1 year postoperatively (9-12 months after surgery). The factors analyzed that were potentially associated with the use of analgesics included chronic diseases at the time of surgery (according to the Special Reimbursement Register data). In addition, clinical data were extracted from the prospective database of the hospital that included age, gender, body mass index (BMI), laterality (unilateral/bilateral) of the operation, prosthesis type (for knees: unicompartmental / total knee replacement), and Harris Hip Score for hip patients and Knee Society Knee and Function Score for knee patients.

A modified Charlson’s comorbidity index score (28) was calculated for each patient based on the drug reimbursement data. A score of 1 was assigned for heart failure, coronary artery disease, diabetes type I or type II, chronic asthma or other severe obstructive pulmonary disease, dementia,
disseminated connective tissue diseases, and rheumatoid arthritis and other comparable conditions. A score of 2 was assigned for uremia requiring dialysis, severe anemia in connection with chronic renal failure, leukemia and other malignant diseases of blood and bone marrow (including malignant diseases of the lymphatic system), and cancer (including breast and prostate cancers, female genital tract cancer, and malignant neoplasms).

Although differences in the trajectories of analgesic consumption among hip and knee replacement patients were reported in a previous analysis (27), in this study, the risk factors for the use of analgesics postoperatively were nearly identical. Therefore, the results for hips and knees are shown together, except for the analyses concerning the effects of laterality, prosthesis type, and hip and knee scores.

The analyses were performed using IBM SPSS Statistics 24. Parametric variables are presented with mean and standard deviation (SD). Unpaired T-test was used to compare parametric variables and chi-square test was used to compare categorical variables. Univariate and multivariate logistic regression analyses were used to calculate odds ratios (OR) with 95% confidence intervals (CI) for using different types of analgesics. Adjustments in the multivariate model included age, gender, joint, BMI, Charlson Comorbidity Index score, preoperative purchases of antidepressants, and laterality (bilateral/unilateral). P-values of <0.05 were considered statistically significant.

Ethics and registration
The use of drug register data was approved by the Social Insurance Institution of Finland, and permission to use other patient-related data was applied for from the hospital authorities responsible for that data. As this was a retrospective register study, no consent from the Ethical Board or the patients was required.

Results
The mean age of the study population was 68.7 years (67.6 years for hip patients and 69.7 years for knee patients) and 61.1% were women. Mean BMI was 29.1 kg/m² (28.2 for hip patients and 29.9 on knee patients). Comorbidities are shown in Table 1.

Three months preoperatively, 43.1% of patients redeemed at least one type of analgesic drug, most
commonly NSAIDs (29.7%), followed by acetaminophen (12.8%), and opioids (11.3%). One year after surgery, the proportion of patients who redeemed at least one type of analgesic drug decreased to 26.1%, and NSAIDs were still the most common (15.5%), followed by acetaminophen (10.1%), and opioids (6.7%).

Patient characteristics
A higher proportion of older patients redeemed any analgesic drug one year postoperatively (29.0% of patients aged >75 years) than younger patients (26.2% of patients aged 65-75 years, and 23.7% of patients aged <65 years; p<0.001) (Appendix 1). In the adjusted model, patients older than 75 years (reference <65 years) had higher odds for the use of any analgesic drug (OR 1.3 [95% CI: 1.2–1.4]), and acetaminophen (2.4 [2.0–2.8]), and lower odds for the use of NSAIDs (OR 0.73 [0.64–0.84]) (Table 2). A higher proportion of women (28.8%) than men (22.0%) redeemed any analgesic drug postoperatively (p<0.001). In the adjusted model, women had higher odds for the use of any analgesics, acetaminophen, and NSAIDs, but not opioids (Table 2).

Comorbidities
High body mass index (BMI) was associated with the use of any analgesic drugs (Figure 2). One year postoperatively, 22.7% of patients with BMI <25, 24.5% of patients with BMI 25-30, 27.7% of patients with BMI 30-35, and 29.0% of patients with BMI >35 redeemed analgesics (p<0.001). In the adjusted model, patients with BMI >35 kg/m2 (reference <25 kg/m2) had higher odds for the use of any analgesic drug, acetaminophen, NSAIDs, and opioids (Table 2). BMI was also associated with the odds of drug use as a constant variable (Table 2).

A high Charlson comorbidity index (CCI) score was associated with any analgesic drug use both pre- and postoperatively. Postoperatively, 24.1% of patients with a score of 0, 30.7% of patients with a score of 1, and 33.1% of patients with a score of 2 or more redeemed any analgesic drug (Appendix 1). In the adjusted model, a CCI score of 2 or more was associated with higher odds for the use of any analgesic drugs (OR 1.4 [1.2–1.6]), acetaminophen (OR 1.5 [1.2–1.8]), and opioids (OR 2.0 [1.6–2.5]). The results were similar when patients with a history of malignancy were excluded (data not shown). Although many of the individual comorbidities were associated with a greater proportions of users of
any analgesic drug postoperatively (Appendix 1), after adjustments, only hypertension was associated with a higher use of any analgesic drug (OR 1.1 [1.00–1.2]), whereas chronic lung disease was associated with the use of NSAIDs (OR 1.3 [1.04–1.6]), and epilepsy was associated with use of opioids (OR 2.1 [1.2–3.5]). Cardiac disease, however, was associated with lower odds for using NSAIDs (OR 0.73 [0.60–0.88]) (Table 2). Neurodegenerative disease was associated with higher odds for using acetaminophen (OR 1.6 [1.1–2.3]).

Other clinical factors
A higher proportion of knee patients than hip replacement patients used any analgesic drug 9-12 months postoperatively (28.8% vs 23.0%, p<0.001) and differences in the use of any analgesic drugs, acetaminophen, NSAIDs, and opioids remained the same after adjustments (Table 2, Appendix 1). Patients who had redeemed any analgesic drugs preoperatively also redeemed them more often postoperatively (40.6% vs 15.2%, p<0.001) and similar results were seen in the adjusted model (Table 2, Appendix 1).

Joint-specific issues
Patients receiving bilateral hip or knee replacements tended to use fewer analgesics postoperatively (Appendix 1). However, in the adjusted analyses, statistically significant differences were only observed for acetaminophen both after hip and knee replacement and opioids after knee replacement (Table 3). A higher proportion of total knee replacement patients than unicompartmental knee replacement patients used any analgesic drugs (29.1% vs 23.5%, p=0.007) (Appendix 1). In the adjusted model, patients with unicompartmental knee replacement had lower odds for the use of acetaminophen (OR 0.45 [0.27–0.74]) and opioids (0.54 [0.32–0.91]) after surgery (Table 3). Both before hip and knee replacement, a worse preoperative situation, as measured with the Harris Hip Score and Knee Society Score, respectively, was associated with a greater use of analgesics (Table 3), but postoperatively there were practically no differences.

Discussion
This large study of an unselected osteoarthritis population undergoing hip or knee replacement found that higher age, female gender, obesity, number of comorbidities (according to modified Charlson Comorbidity Index score), preoperative use of analgesics, and unilateral knee replacement (compared
to simultaneous bilateral procedure) were associated with a higher probability of using analgesic drugs one year after surgery, whereas individual comorbid conditions had little or no effect. The present study expands on the earlier literature by analyzing the impact of several comorbidities and clinical factors on the postoperative consumption of all analgesic drugs, and by including not only NSAIDs and opioids, but also acetaminophen.

Our main finding is that obesity was associated with higher odds for the consumption of all the studied analgesic drugs both pre- and postoperatively. Previously, a higher BMI has been shown to predict NSAID use after THA and TKA (11,12,21), and opioid use after TKA (11,17). Our study shows that obesity predicts the use of all analgesic drugs (acetaminophen, NSAIDs, and opioids) after hip or knee replacement. Similar to the findings of earlier studies (11,12,21), drug use increased, especially when patient BMI exceeded 35 kg/m2. Obese patients report more pain after joint replacement (7,21), which is one possible explanation for this finding.

The number of comorbidities measured with CCI score predicted the use of acetaminophen and opioids, but not NSAIDs. Earlier, Hansen et al. (16) reported an association between higher CCI score and chronic opioid use after TKA. We were, however, unable to provide a good explanation for this finding. A history of malignancy, a component of the CCI with a score of 2, could be one possible explanation, but a CCI score of 1 also predicted analgesics use, and the results considering CCI in the logistic regression were identical, even when patients with a history of malignancy were excluded. Additionally, a history of malignancy was not independently associated with analgesic use.

Out of the separate comorbidities, patients with neurodegenerative disorders used acetaminophen (but not NSAIDs or opioids) more often. This may be related to the adverse events of opioids and NSAIDs in long-term use in the elderly (23,24,29–31). As expected, patients with cardiac disease used fewer NSAIDs than other patients (23,24). Patients with epilepsy use more opioids in the general population (32), possibly due to a higher prevalence of painful conditions, and we found a similar finding in joint replacement recipients. Interestingly, although diabetes is associated with persistent postoperative pain, the disease was not associated with analgesic consumption, especially when their higher BMIs were taken into account (7). Earlier, controversial results have been reported regarding
diabetes (9,17).

Patients who underwent knee surgery used acetaminophen, NSAIDs, and opioids more often than patients who underwent hip surgery (12,15,18). Patients with simultaneous bilateral knee surgery used more analgesics preoperatively (compared to unilateral operation) but used fewer opioids and acetaminophen postoperatively. These findings may reflect patient selection bias as those patients with previous opioid use or signs of a history of pain sensitization are not candidates for simultaneous bilateral knee arthroplasty. It is not known whether simultaneous or staged bilateral operation should be preferred in bilateral osteoarthritis (33), and a comparison of these procedures was not possible in the present study due to the chosen exclusion criteria (another joint replacement 2 years before or after index surgery; therefore, patients with staged bilateral operations were excluded). Similar to the findings of earlier studies (9,13), UKA (compared to TKA) was associated with lower odds for the use of opioids and acetaminophen.

In line with earlier studies (13,15,17,18,26), preoperative analgesic use was associated with greater postoperative opioid use. In this study, we also found a similar association with the use of acetaminophen and NSAIDs. Furthermore, opioid consumption was greater in patients with higher CCI score, epilepsy, obesity (BMI >35 kg/m²), knee vs hip surgery, unilateral knee replacement vs bilateral operation, TKA vs UKA, and those who used analgesics preoperatively. Previously, increased opioid consumption after hip and knee replacement has been associated with TKA vs THA, preoperative opioid or other analgesic use, psychiatric disorders (especially depression/anxiety), tobacco use, cardiac disease, younger age, greater affected joint pain, other pain sites, TKA vs UKA, use of walking aids, and female gender (9,11,13,15-18,20,21,26). In addition, obesity and the number of comorbidities (based on CCI score) have been associated with increased opioid use after knee replacement (11,17). The new findings in this study were that obesity, epilepsy, and overall comorbidity (based on modified CCI score) were associated with greater opioid use after both hip and knee replacement.

The main strength of our study is the inclusion of all analgesic drug groups (acetaminophen, NSAID, opioid) in a large sample of unselected joint replacement patients. We included only primary joint
replacements and only osteoarthritis as an indication for surgery. Other indications were excluded because, for example, patients with rheumatoid arthritis tend to have polyarticular involvement more often, which serves to hamper the analysis of the use of analgesic drugs. Patients with revision or other joint replacement during the follow-up period were excluded because the perioperative peak in the consumption of analgesic drugs related to the latter operation would have been a potentially confounding factor considering the analysis of postoperative analgesic use after index surgery. According to our previous analysis (27), 9-12 months after surgery appears to be a suitable time point for analyzing the level of postoperative analgesic use. Because the use patterns are similar after hip and knee replacement and also among different comorbid conditions, the materials could be analyzed as a whole to increase statistical power. All operations were performed in a single orthopaedic hospital with standardized perioperative care, anesthesia, and analgesia. Medication data include all the prescribed medications that were dispensed in Finland. The presence of comorbidities was based on a nationwide Reimbursement Register that covers the most important comorbidities, although a clear limitation is that the register does not cover mental health problems other than psychotic disorders. However, we included the use of antidepressants in the adjusted model, along with several other possible confounders.

The limitations of the study include the lack of information on OTC-drugs and the fact that in a register study based on redeemed prescriptions, it is not possible to find out the indication for the analgesic drug (index joint or other pain sites) nor whether the patient has taken the drug or not. For these reasons, the actual use of acetaminophen and NSAIDs (that are available OTC) might be higher than reported here, but it is unlikely that this would have affected the use patterns or associated factors. Although patients with major complications leading to revision were excluded, we were not able to analyze all postoperative complications. Moreover, the intensity of pain and the prevalence of persistent pain were not examined in this study.

Conclusions
In conclusion, higher age, female gender, obesity, number of comorbidities (according to modified Charlson Comorbidity Index score), preoperative use of analgesics, and unilateral knee replacement
(compared to simultaneous bilateral procedure) were associated with the probability of using analgesic drugs 1 year after joint replacement. The strongest predictors of increased postoperative use of analgesics were obesity (especially BMI >35 kg/m2) and the preoperative use of analgesics. It is remarkable that older age and higher number of comorbidities predicted analgesic use despite these patients also being the most vulnerable to adverse drug events. Clinicians should therefore inform patients with obesity (especially BMI >35 kg/m2) about the elevated risk for prolonged use of analgesics (including opioids) after surgery.

Abbreviations
ATC code = Anatomical Therapeutic Chemical code
BMI = body mass index
CCI score = Charlson’s comorbidity index score
CI = Confidence interval
NSAID = non-steroidal anti-inflammatory drug
OR = odds ratio
OTC drug = over-the-counter drug
SD = standard deviation
SII Social Insurance Institution
THA = total hip arthroplasty
TKA = total knee arthroplasty
UKA = unicompartmental knee arthroplasty

Declarations
Ethics approval and consent to participate
The study was approved by the Social Insurance Institution of Finland (Kela), from where the medication data were extracted and by the hospital, from where the clinical data were extracted. According to Finnish and EU legislation, consent from the patients or from the Ethical Board was not required because this was a retrospective register study.

Consent for publication
Not applicable.

Availability of data and material
National legislation and data protection regulations do not allow the sharing of the patient-level materials of this study. Summarized data (such as patient numbers) can be provided by corresponding author upon request.

**Competing interests**

EJ, TM, and AH have received payments for lectures not related to this manuscript from pharmaceutical and other medical companies. The authors PP and TR declare that they have no competing interests.

**Funding**

This study was financially supported by the Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital. The Funding organization did not have any role in the design of the study or the collection, analysis, and interpretation of the data or in the writing of the manuscript.

**Authors' contributions**

EJ, TR, TM, PP, and AH designed the study. TR analyzed the data, wrote the first draft of the manuscript and took care of its revisions under the supervision of EJ. All the authors contributed to interpretation of the results and preparation of the manuscript. All authors approved the final version of the manuscript.

**Acknowledgements**

We thank Heini Huhtala, M.Sc., for her assistance with statistical analyses.

**Authors' information (optional)**

Not applicable.

**References**

1. Ferguson RJ, Palmer AJ, Taylor A, Porter ML, Malchau H, Glyn-Jones S. Hip replacement. Lancet (London, England). 2018 Nov;392(10158):1662–71.

2. Price AJ, Alvand A, Troelsen A, Katz JN, Hooper G, Gray A, et al. Knee replacement. Lancet (London, England). 2018 Nov;392(10158):1672–82.

3. Beswick AD, Wylde V, Gooberman-Hill R, Blom A, Dieppe P. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis?
A systematic review of prospective studies in unselected patients. BMJ Open [Internet]. 2012;2(1):e000435. Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2011-000435

4. Blom AW, Artz N, Beswick AD, Burston A, Dieppe P, Elvers KT, et al. Improving patients’ experience and outcome of total joint replacement: the RESTORE programme [Internet]. Improving patients’ experience and outcome of total joint replacement: the RESTORE programme. NIHR Journals Library; 2016 [cited 2017 Jan 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27559567

5. Lewis GN, Rice DA, McNair PJ, Kluger M. Predictors of persistent pain after total knee arthroplasty: A systematic review and meta-analysis. Br J Anaesth. 2015;114(4):551–61.

6. Lungu E, Maftoon S, Vendittoli P, Desmeules F. Review article A systematic review of preoperative determinants of patient-reported pain and physical function up to 2 years following primary unilateral total hip arthroplasty. Orthop Traumatol Surg Res [Internet]. 2016;102(3):397–403. Available from: http://dx.doi.org/10.1016/j.otsr.2015.12.025

7. Rajamäki TJ, Jämsen E, Puolakka PA, Nevalainen PI, Moilanen T. Diabetes is associated with persistent pain after hip and knee replacement. Acta Orthop [Internet]. 2015;86(5):586–93. Available from: http://www.tandfonline.com/doi/full/10.3109/17453674.2015.1044389

8. Schwenk ES, Pozek J-PJ, Viscusi ER. Managing Prolonged Pain After Surgery: Examining the Role of Opioids. J Arthroplasty. 2018 Nov;33(11):3389–93.

9. Fuzier R, Serres I, Bourrel R, Palmaro A, Montastruc J-L, Lapeyre-Mestre M. Analgesic drug consumption increases after knee arthroplasty: A pharmacoepidemiological study investigating postoperative pain. Pain [Internet]. 2014 Jul [cited 2018 Apr
10. Blågestad T, Nordhus IH, Grønli J, Engesæter LB, Ruths S, Ranhoff AH, et al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hypnotics, antidepressants, and anxiolytics. Pain [Internet]. 2016;157(3):643–51. Available from: https://insights.ovid.com/crossref?an=00006396-201603000-00016

11. Singh JA, Lewallen DG. Predictors of use of pain medications for persistent knee pain after primary Total Knee Arthroplasty: a cohort study using an institutional joint registry. Arthritis Res Ther [Internet]. 2012;14(6):R248. Available from: http://arthritis-research.biomedcentral.com/articles/10.1186/ar4091

12. Bolland BJRF, Culliford DJ, Maskell J, Latham JM, Dunlop DG, Arden NK. The effect of hip and knee arthroplasty on oral anti-inflammatory use and the relationship to body mass index: Results from the UK general practice research database. Osteoarthr Cartil [Internet]. 2011;19(1):29–36. Available from: http://dx.doi.org/10.1016/j.joca.2010.10.012

13. Bedard NA, DeMik DE, Dowdle SB, Callaghan JJ. Trends and risk factors for prolonged opioid use after unicompartmental knee arthroplasty. Bone Joint J. 2018 Jan;100-B(1 Supple A):62–7.

14. Inacio MCS, Hansen C, Pratt NL, Graves SE, Roughead EE. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open [Internet]. 2016;6(4):e010664. Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2015-010664

15. Goesling J, Moser SE, Zaidi B, Hassett AL, Hilliard P, Hallstrom B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain [Internet]. 2016 Jun [cited 2018 Apr 14];157(6):1259–65. Available from:
16. Hansen CA, Inacio MCS, Pratt NL, Roughead EE, Graves SE. Chronic Use of Opioids Before and After Total Knee Arthroplasty: A Retrospective Cohort Study. J Arthroplasty [Internet]. 2017;32(3):811-817.e1. Available from: http://dx.doi.org/10.1016/j.arth.2016.09.040

17. Namba RS, Singh A, Paxton EW, Inacio MCS. Patient Factors Associated With Prolonged Postoperative Opioid Use After Total Knee Arthroplasty. J Arthroplasty. 2018 Aug;33(8):2449–54.

18. Jørgensen CC, Petersen M, Kehlet H, Aasvang EK. Analgesic consumption trajectories in 8975 patients 1 year after fast-track total hip or knee arthroplasty. Eur J Pain. 2018;22(April):1428–38.

19. Bolarinwa S, Casp AA, Cancienne JM, Werner BC, Browne JA. Narcotic use and total hip arthroplasty. Hip Int. 2018 Jun;1120700018781759.

20. Hsia H-L, Takemoto S, van de Ven T, Pyati S, Buchheit T, Ray N, et al. Acute Pain Is Associated With Chronic Opioid Use After Total Knee Arthroplasty. Reg Anesth Pain Med. 2018 Oct;43(7):705–11.

21. Singh JA, Lewallen D. Predictors of pain and use of pain medications following primary Total Hip Arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years. BMC Musculoskelet Disord [Internet]. 2010 May 13 [cited 2018 Apr 14];11(1):90. Available from: http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-11-90

22. de Leon-Casasola OA. Opioids for chronic pain: new evidence, new strategies, safe prescribing. Am J Med [Internet]. 2013;126(3 Suppl 1):S3-11. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002934312009205

23. Scarpignato C, Lanas A, Blandizzi C, Lems WF, Hermann M, Hunt RH. Safe prescribing
of non-steroidal anti-inflammatory drugs in patients with osteoarthritis—an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar;13:55.

24. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014 Oct;70(10):1159-72.

25. Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A Brief History of the Opioid Epidemic and Strategies for Pain Medicine. Pain Ther. 2018 Jun;7(1):13-21.

26. Bedard NA, Pugely AJ, Dowdle SB, Duchman KR, Glass NA, Callaghan JJ. Opioid Use Following Total Hip Arthroplasty: Trends and Risk Factors for Prolonged Use. J Arthroplasty. 2017 Dec;32(12):3675-9.

27. Rajamäki T, Puolakka P, Hietaharju A, Moilanen T, Jämsen E. Use of prescription analgesic drugs before and after hip or knee replacement in patients with osteoarthritis. BMC Musculoskelet Disord. 2019;20(1):427.

28. Taipale H, Tanskanen A, Koponen M, Tolppanen A-M, Tiihonen J, Hartikainen S. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014 Jul;29(4):216-23.

29. Ennis ZN, Dideriksen D, Vaegter HB, Handberg G, Pottegård A. Acetaminophen for Chronic Pain: A Systematic Review on Efficacy. Basic Clin Pharmacol Toxicol [Internet]. 2016;118(3):184-9. Available from: http://doi.wiley.com/10.1111/bcpt.12527

30. de Leon-Casasola OA. Opioids for Chronic Pain: New Evidence, New Strategies, Safe Prescribing. Am J Med [Internet]. 2013 Mar [cited 2018 Apr 14];126(3):53-11.
Table 1. Demographic characteristics

|                          | Hip replacement | Knee replacement |
|--------------------------|-----------------|------------------|
| Total number, n          | 6238            | 7501             |
| Age, mean (SD), years    | 67.59 (10.63)   | 69.67 (9.52)     |
| Female                   | 53.2%           | 67.7%            |
| Bilateral operation, n   | 418 (6.7%)      | 1225 (16.3%)     |
| BMI, mean (SD), kg/m²    | 28.2 (4.7)      | 29.9 (4.8)       |
| Charlson Comorbidity Index** |
| 0                        | 4685 (75.1%)    | 5239 (69.8%)     |
| 1                        | 1128 (18.1%)    | 1621 (21.6%)     |
| >2                       | 425 (6.8%)      | 641 (8.5%)       |
| Diabetes, n (%)          | 373 (6.0%)      | 619 (8.3%)       |
| Cardiac disease***, n (%)| 1656 (26.5%)    | 2491 (33.2%)     |
| Psychotic disorder, n (%)| 182 (2.9%)      | 273 (3.6%)       |
| Neurodegenerative disease (Alzheimer or Parkinson) |
| n (%)                    | 86 (1.4%)       | 111 (1.5%)       |
| Pulmonary disease, n (%) | 425 (6.8%)      | 641 (8.5%)       |
| Hypertension, n (%)      | 1128 (18.1%)    | 1621 (21.6%)     |
| History of malignancy, n (%) | 182 (2.9%) | 273 (3.6%) |
| Epilepsy, n (%)          | 67 (1.1%)       | 74 (1.0%)        |
| Antidepressant****, n (%)| 621 (10.0%)     | 840 (11.2%)      |
| KSS Knee Score, n (%)    | 3965 (52.9%)    | 3965 (52.9%)     |
| Poor (<60)               | 4685 (75.1%)    | 5239 (69.8%)     |
| Fair (60-70)             | 3801 (60.9%)    | 3801 (60.9%)     |
| Good or Excellent (>70)  | 2760 (36.8%)    | 2760 (36.8%)     |
| missing                  | 240 (3.8%)      | 240 (3.8%)       |
| KSS Function Score, n (%)|
| Poor (<60)               | 4623 (63.3%)    | 4623 (63.3%)     |
| Fair (60-70)             | 1473 (19.6%)    | 1473 (19.6%)     |
| Good or Excellent (>70)  | 2645 (35.3%)    | 2645 (35.3%)     |
| missing                  | 2138 (30.4%)    | 2138 (30.4%)     |
| Harris Hip Score, n (%)  |
| Poor (<70)               | 3801 (60.9%)    | 3801 (60.9%)     |
| Fair (70-80)             | 240 (3.8%)      | 240 (3.8%)       |
| Good or Excellent (>80)  | 59 (0.9%)       | 59 (0.9%)        |
| missing                  | 2138 (30.4%)    | 2138 (30.4%)     |

SD=standard deviation
*missing on 825 (13.2%) of hip and 997 (13.3%) of knee patients
** Modified Charlson comorbidity Index
***coronary artery disease, heart failure, chronic arrhythmia
****Redeemed antidepressant one year before surgery
## Table 2. Multivariable adjusted odds ratios for analgesic consumption

|                        | Preoperative (0-3 months) | Postoperative (9-12 months) |
|------------------------|----------------------------|------------------------------|
|                        | Any analgesic*             | Any analgesic*               |
| Age, years             |                            |                              |
| <65                    | 1                          | 1                            |
| 65-75                  | 1.02 (0.93-1.1)            | 1.2 (1.04-1.3)               |
| >75                    | 1.00 (0.91-1.1)            | 1.3 (1.2-1.5)                |
| Female Gender          |                            |                              |
| <25                    | 1                          | 1                            |
| 25-30                  | 1.1 (0.96-1.2)             | 1.1 (0.96-1.2)               |
| >35                    | 1.6 (1.4-1.8)              | 1.7 (1.5-2.0)                |
| BMI, constant, per increase of 1 kg/ m² |                |                              |
| <25                    | 1                          | 1                            |
| 25-30                  | 1.1 (0.96-1.2)             | 1.1 (0.96-1.2)               |
| >35                    | 1.6 (1.4-1.8)              | 1.7 (1.5-2.0)                |
| Charlson comorbidity index*** |            |                              |
| 0                      | 1                          | 1                            |
| 1                      | 1.1 (1.00-1.2)             | 1.3 (1.1-1.4)                |
| 2 or more              | 1.2 (1.03-1.4)             | 1.4 (1.2-1.6)                |
| Diabetes               |                            |                              |
| No                     | 1                          | 1                            |
| Yes, but without insulin medication | 0.99 (0.91-1.1) | 1.1 (0.99-1.2) |
| Yes, with insulin medication | 1.0 (0.88-1.2) | 0.95 (0.80-1.1) |
| Cardiac disease****    | 0.76 (0.66-0.87)           | 0.92 (0.80-1.1)              |
| Psychotic disorder     | 1.1 (0.83-1.5)             | 1.2 (0.91-1.7)               |
| Neurodegenerative disease***** | 1.2 (0.89-1.7) | 1.1 (0.77-1.5) |
| Chronic lung disease   | 1.1 (0.97-1.3)             | 1.1 (0.96-1.3)               |
| Hypertension           | 1.04 (0.95-1.1)            | 1.1 (1.00-1.2)               |
| History of malignancy | 1.2 (0.93-1.6)             | 1.07 (0.80-1.4)              |
| Epilepsy               | 1.2 (0.83-1.7)             | 1.4 (0.94-2.0)               |
| Knee replacement vs hip replacement | 0.63 (0.58-0.68) | 1.3 (1.2-1.4)               |
| Preoperative analgesic use****** |            | 4.0 (3.6-4.3)               |

* acetaminophen, NSAID, opioid
** OR (95% CI) adjusted with age (constant), gender, joint, Charlson Comorbidity Index, BMI (constant), laterality (unilateral
*** Modified Charlson comorbidity Index
**** Coronary artery disease, heart failure, chronic arrythmia
***** Alzheimer's or Parkinson's disease
****** Use of any analgesic drug (acetaminophen, NSAID, and/or opioid) preoperatively
| Table 3. Multivariable adjusted odds ratios for analgesic consumption according to clinical factors |
|-----------------------------------------------|-----------------|-----------------|
| | Preoperative (0-3 months) | Postoperative (9-12 months) |
| | Any analgesic* | Any analgesic* |
| | Adjusted OR** | Adjusted OR** |
| Hip replacement | | |
| Laterality:bilateral | | |
| Harris Hip Score*** | | |
| Poor (<70) | 1 | 1 |
| Fair (70-80) | 0.65 (0.48-0.88) | 0.75 (0.50-1.1) |
| Good or Excellent (>80) | 0.36 (0.19-0.69) | 0.55 (0.23-1.1) |
| Knee replacement | | |
| Laterality:bilateral | | |
| UKA (vs TKA) | | |
| Poor (<60) | 1 | 1 |
| Fair (60-70) | 0.72 (0.60-0.87) | 0.92 (0.76-1.1) |
| Good or Excellent (>70) | 0.69 (0.52-0.91) | 0.84 (0.62-1.1) |
| KSS Knee Score*** | | |
| Poor (<60) | 1 | 1 |
| Fair (60-70) | 0.89 (0.73-1.1) | 1.03 (0.84-1.3) |
| Good or Excellent (>70) | 0.84 (0.72-0.98) | 0.86 (0.73-1.01) |

* acetaminophen, NSAID, opioid
**OR (95% CI) adjusted with age (constant), gender, Charlson Comorbidity Index, BMI (constant), laterality (unilateral vs bilateral) and use of antidepressant 1 year before surgery
*** HHS missing on 2138 patients and KSS on 2617 patients

Figures
13,261 hip and 13,205 knee replacements

- Not primary operation
  3645 hip replacements
  1792 knee replacements

9,616 primary hip and 11,413 primary knee replacements

- Not primary OA as indication
  1764 hip replacements
  1096 knee replacements

7,852 hip and 10,317 knee replacements for OA

- Revision or other joint replacement in the study period
  1614 hip replacements
  2816 knee replacements

Study population
6,238 hip replacements
  • 5,657 patients
7,501 knee replacements
  • 6,791 patients

Figure 1
Study population
Figure 2

The proportions of patients with any analgesic drugs in three months intervals according to BMI. Time periods used in the adjusted analyses are marked with * (preoperative) and ** (postoperative).